Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + Chemotherapy in Non-responders to Neoadjuvant Chemotherapy for Breast Cancer
NCT06596018Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Dec 2024
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast adenocarcinoma (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Breast conservation rate and Pathological Complete Response up to 21 weeks. Started Dec 2024; status: recruiting.
02
Conditions
breast adenocarcinoma
Beyond the preview
Go deeper on NCT06596018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06596018.